Greg Basarab has an appointment as Principal Research Officer and Associate Director at the University of Cape Town (UCT) and the affiliated Drug Discovery and Development Centre (H3D). He leads research teams in Medicinal Chemistry, DMPK and Microbiology directed toward the eradication of infectious diseases including malaria and tuberculosis. He contributes lectures in Pharmacology, Toxicology and Medicinal Chemistry at UCT and sits on scientific advisory boards of CARB-X (Combating Antibiotic Resistant Bacteria and the South Africa MRC (Medical Research Council). Previously, he was an Associate Director at AstraZeneca where he led multi-disciplinary teams in infectious disease drug discovery and delivered three candidate drugs to clinical trials, including zoliflodacin, currently in Phase 3 for the treatment of gonorrhea. Before that, he worked at DuPont leading projects in three departments: Central Research & Development, Biochemicals and Agricultural Products in the antifungal arena and in automated chemistry. He has a B.S. and PhD in Chemistry from Penn State University and MIT, respectively.